Genmab Updates Articles of Association, Expands Capital and Incentive Authorizations

The latest update is out from Genmab ( (GMAB) ).

Genmab has updated and filed its Articles of Association with the U.S. Securities and Exchange Commission in a Form 6-K dated February 25, 2026, detailing its capital structure, governance framework and authorizations. The company’s share capital is set at DKK 64,250,721 in nominal DKK 1 shares, with provisions for share issuance, shareholder rights and general meeting procedures.

The board is authorized until March 12, 2029 to increase share capital by up to nominally DKK 6.6 million, both with and without pre-emptive rights, supporting strategic financing flexibility. Genmab also maintains several warrant and convertible debt programs for employees and investors, with authorizations running as far as March 11, 2030, underscoring a long-term equity-based incentive structure and potential future dilution for shareholders.

Warrant authorizations from general meetings in 2021, 2024 and 2025 allow issuance of up to DKK 750,000 nominal shares per program to employees of Genmab and its subsidiaries, excluding executive management. Existing shareholders do not have pre-emption rights on warrant-based share issues, and the board may re-use or re-issue lapsed warrants, giving management broad tools for talent retention and alignment.

Separately, the board may issue convertible debt instruments enabling conversion into up to nominally DKK 3 million in new shares without pre-emption rights, at prices at least equal to market value. Combined use of the share and convertible authorizations is capped at a nominal DKK 6.6 million capital increase, balancing capital-raising capacity with defined limits for current investors.

The most recent analyst rating on (GMAB) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.

The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab A/S is a Danish biotechnology company based in Copenhagen that focuses on medical research, as well as the production and sale of related products. The group operates in the biopharmaceutical sector, developing therapies grounded in advanced research, and its corporate language is English, reflecting an international investor and partner base.

Average Trading Volume: 1,705,631

Technical Sentiment Signal: Buy

Current Market Cap: $17.98B

For detailed information about GMAB stock, go to TipRanks’ Stock Analysis page.